# A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer

> **NCT06016270** · PHASE1,PHASE2 · TERMINATED · sponsor: **STCube, Inc.** · enrollment: 10 (actual)

## Conditions studied

- Extensive Stage Small Cell Lung Cancer

## Interventions

- **DRUG:** hSTC810 400 mg + Paclitaxel
- **DRUG:** hSTC810 800 mg + Paclitaxel

## Key facts

- **NCT ID:** NCT06016270
- **Lead sponsor:** STCube, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-02-13
- **Primary completion:** 2025-01-23
- **Final completion:** 2025-08-25
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Company strategy
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06016270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06016270, "A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06016270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*